AU2002329061A1 - Gene and protein relating to hepatocellular carcinoma - Google Patents

Gene and protein relating to hepatocellular carcinoma

Info

Publication number
AU2002329061A1
AU2002329061A1 AU2002329061A AU2002329061A AU2002329061A1 AU 2002329061 A1 AU2002329061 A1 AU 2002329061A1 AU 2002329061 A AU2002329061 A AU 2002329061A AU 2002329061 A AU2002329061 A AU 2002329061A AU 2002329061 A1 AU2002329061 A1 AU 2002329061A1
Authority
AU
Australia
Prior art keywords
gene
hepatocellular carcinoma
protein relating
protein
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002329061A
Other languages
English (en)
Inventor
Yoichi Furukawa
Yusuke Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
The University of Tokyo
Original Assignee
Oncotherapy Science Inc
The University of Tokyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA 2399569 external-priority patent/CA2399569A1/en
Application filed by Oncotherapy Science Inc, The University of Tokyo filed Critical Oncotherapy Science Inc
Publication of AU2002329061A1 publication Critical patent/AU2002329061A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2002329061A 2001-09-25 2002-09-25 Gene and protein relating to hepatocellular carcinoma Abandoned AU2002329061A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US32426101P 2001-09-25 2001-09-25
US60/324,261 2001-09-25
US39166602P 2002-06-26 2002-06-26
US60/391,666 2002-06-26
CA 2399569 CA2399569A1 (en) 2001-09-25 2002-08-23 Diagnostic markers and drug targets for treatment of cancer
CA2,399,569 2002-08-23
PCT/JP2002/009876 WO2003027143A2 (en) 2001-09-25 2002-09-25 Gene and protein relating to hepatocellular carcinoma

Publications (1)

Publication Number Publication Date
AU2002329061A1 true AU2002329061A1 (en) 2003-04-07

Family

ID=27171637

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002329061A Abandoned AU2002329061A1 (en) 2001-09-25 2002-09-25 Gene and protein relating to hepatocellular carcinoma

Country Status (9)

Country Link
US (3) US7767392B2 (enExample)
EP (1) EP1430152B1 (enExample)
JP (1) JP4353798B2 (enExample)
CN (1) CN1628179B (enExample)
AT (1) ATE356223T1 (enExample)
AU (1) AU2002329061A1 (enExample)
DE (1) DE60218710T2 (enExample)
ES (1) ES2283592T3 (enExample)
WO (1) WO2003027143A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
DE60218710T2 (de) 2001-09-25 2007-12-06 Oncotherapy Science, Inc., Kawasaki Gen und protein mit bezug zu hepatozellulärem karzinom
EP2311948A1 (en) * 2003-02-28 2011-04-20 Onco Therapy Science, Inc. RNA-interference for ZNFN3A1-gene as a method for inhibiting cancer cell growth
WO2005028675A2 (en) * 2003-09-24 2005-03-31 Oncotherapy Science, Inc. Methods for detecting, diagnosing and treating hepatocellular carcinomas (hcc)
TWI350373B (en) * 2004-01-23 2011-10-11 Oncotherapy Science Inc Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators
US20060189560A1 (en) * 2005-01-27 2006-08-24 Ajit Kumar Molecular method to augment RNA mediated gene silencing
JP4851451B2 (ja) * 2005-02-28 2012-01-11 オンコセラピー・サイエンス株式会社 乳癌関連遺伝子ｚｎｆｎ３ａ１
WO2006121208A1 (en) * 2005-05-12 2006-11-16 Oncotherapy Science, Inc. Polymorphisms of the e2f-1 binding element and methods of determining cancer susceptibility
TW200741009A (en) 2005-07-01 2007-11-01 Oncotherapy Science Inc Methods of modulating SMYD3 for treatment of cancer
JP5272134B2 (ja) 2007-06-14 2013-08-28 オンコセラピー・サイエンス株式会社 Ｓｍｙｄ３によるｖｅｇｆｒ１のメチル化調整因子を同定する方法
EP2405269B8 (en) 2009-03-05 2016-10-12 National Institute of Advanced Industrial Science And Technology Method for detecting and distinguishing intrahepatic cholangiocarcinoma
WO2011011366A2 (en) * 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
EP2785870B1 (en) 2011-12-02 2017-05-03 OncoTherapy Science, Inc. Smyd2 as a target gene for cancer therapy and diagnosis
WO2014141652A1 (en) * 2013-03-11 2014-09-18 Oncotherapy Science, Inc. Smyd3 peptides and vaccines containing the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999039200A1 (en) 1998-01-29 1999-08-05 Thomas Jefferson University Molecular markers for diagnosing hepatocellular carcinoma
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
WO2000017355A2 (en) 1998-09-18 2000-03-30 Incyte Pharmaceuticals, Inc. Human cytoskeleton associated proteins
AU2743400A (en) * 1999-01-29 2000-08-18 Incyte Pharmaceuticals, Inc. Nucleic-acid binding proteins
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
WO2001029221A2 (en) 1999-10-20 2001-04-26 Zymogenetics, Inc. Proteins and polynucleotides encoding them
AU783762B2 (en) 1999-12-23 2005-12-01 Arca Biopharma, Inc. Methods and materials relating to prothrombinase-like polypeptides and polynucleotides
EP1591448A3 (en) 2000-04-18 2006-01-11 Nuvelo, Inc. Novel nucleic acids and polypeptides
EP1425302A2 (en) 2001-01-24 2004-06-09 Protein Design Labs Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
GB0111218D0 (en) 2001-05-08 2001-06-27 Cancer Res Ventures Ltd Assays methods and means
WO2002092002A2 (en) 2001-05-11 2002-11-21 The Burnham Institute Screening, diagnostic and therapeutic methods relating to riz
WO2003010180A1 (en) 2001-07-23 2003-02-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for rnai mediated inhibition of gene expression in mammals
DE60218710T2 (de) * 2001-09-25 2007-12-06 Oncotherapy Science, Inc., Kawasaki Gen und protein mit bezug zu hepatozellulärem karzinom
CA2399569A1 (en) * 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
US8003315B2 (en) * 2001-12-13 2011-08-23 Exelixis, Inc. TAOJIKs as modifiers of the beta-catenin pathway and methods of use
EP2311948A1 (en) 2003-02-28 2011-04-20 Onco Therapy Science, Inc. RNA-interference for ZNFN3A1-gene as a method for inhibiting cancer cell growth
TWI350373B (en) * 2004-01-23 2011-10-11 Oncotherapy Science Inc Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators
JP4851451B2 (ja) * 2005-02-28 2012-01-11 オンコセラピー・サイエンス株式会社 乳癌関連遺伝子ｚｎｆｎ３ａ１
TW200741009A (en) * 2005-07-01 2007-11-01 Oncotherapy Science Inc Methods of modulating SMYD3 for treatment of cancer
JP5272134B2 (ja) 2007-06-14 2013-08-28 オンコセラピー・サイエンス株式会社 Ｓｍｙｄ３によるｖｅｇｆｒ１のメチル化調整因子を同定する方法

Also Published As

Publication number Publication date
CN1628179A (zh) 2005-06-15
DE60218710T2 (de) 2007-12-06
WO2003027143A2 (en) 2003-04-03
JP4353798B2 (ja) 2009-10-28
EP1430152B1 (en) 2007-03-07
US20040235018A1 (en) 2004-11-25
US20100248240A1 (en) 2010-09-30
WO2003027143A3 (en) 2003-10-30
US20120149762A1 (en) 2012-06-14
DE60218710D1 (de) 2007-04-19
ATE356223T1 (de) 2007-03-15
EP1430152A2 (en) 2004-06-23
US7767392B2 (en) 2010-08-03
JP2005511023A (ja) 2005-04-28
CN1628179B (zh) 2011-04-20
US8148080B2 (en) 2012-04-03
ES2283592T3 (es) 2007-11-01

Similar Documents

Publication Publication Date Title
WO2003027143A3 (en) Gene and protein relating to hepatocellular carcinoma
WO2004031411A3 (en) Genes and polypeptides relating to human pancreatic cancers
WO2004065583A3 (en) Gene expression markers for breast cancer prognosis
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
MY139031A (en) Vaccine composition comprising virus-like particles of human papillomavirus
WO2005028630A3 (en) Engineered zinc finger proteins for regulation of gene expression
HUS1500064I1 (hu) HPV58 L1 optimalizált expressziója élesztõben
LTPA2015049I1 (lt) Žpv 45 l1 optimizuota ekspresija mielėse
WO2002072845A3 (en) Salmonella promoter for heterologous gene expression
ZA200405388B (en) Binding proteins as biosensors
WO2004112829A3 (en) Compositions and methods for the diagnosis and treatment of tumors of glial origin
WO2005044976A3 (en) Oligomeric compounds for use in gene modulation
GB2406169B (en) Methods and compositions relating to labeled rna molecules that reduce gene expression
ATE530911T1 (de) Bindungsproteine als biosensoren
WO2005049075A3 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
WO2005044792A3 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
WO2004013307A3 (en) Compounds for targeting hepatocytes
AU2002324649A1 (en) Haplotype map of the human genome and uses therefor
AU2003262727A1 (en) Thrombospondin fragments and uses thereof in clinical assays for cancer and generation of antibodies and other binding agents
AU2002368056A1 (en) Novel pla2 enzyme, it's antibody, enzyme inhibitor and use and the preparation methods thereof
WO2003055440A8 (en) Compositions and methods for the treatement of immune related diseases
WO2006016525A3 (en) Genes and polypeptides relating to breast cancers
AU2003243381A1 (en) Variants of antithrombin iii
AU1539801A (en) Transcription factors containing two potential dna binding motifs

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase